Taysha Secures FDA Alignment for TSHA-102 BLA, Advances Pivotal Rett Syndrome Trial
TSHA has more than doubled off its 52-week low of $1.05.
Summary
Taysha Gene Therapies announced positive full-year 2025 financial results and a significant corporate update, highlighted by critical progress for its lead gene therapy candidate, TSHA-102, for Rett syndrome. The company has dosed multiple patients in its REVEAL pivotal trial and received FDA clearance to initiate the ASPIRE trial, both on track for Q2 2026 dosing completion. Crucially, Taysha achieved written FDA alignment on its proposed manufacturing and comparability strategy for commercial TSHA-102, as well as on data inclusion for its planned Biologics License Application (BLA) submission to support a broad label. These regulatory and clinical milestones significantly de-risk the development pathway and are highly material for a clinical-stage biotechnology company. Investors will now watch for the completion of dosing in both trials and the longer-term safety and efficacy data from the REVEAL Phase 1/2 trials, all expected in Q2 2026, as key near-term catalysts.
At the time of this announcement, TSHA was trading at $4.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $1.05 to $6.02. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.